Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in Relapsed/Refractory Leukemias
NCT00084916Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by National Cancer Institute. Primary endpoint: Response Rate at 3 years. Started Apr 2004; status: completed.
02
Drugs
temsirolimus
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00084916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084916.